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Abstract
Medulloblastoma (MB) comprises four molecularly and genetically distinct subgroups of embryonal brain tumors
that develop in the cerebellum. MB mostly affects infants and children and is difficult to treat because of frequent
dissemination of tumor cells within the leptomeningeal space. A potential promoter of cell dissemination is the
c-Met proto-oncogene receptor tyrosine kinase, which is aberrantly expressed in many human tumors including
MB. Database analysis showed that c-Met is highly expressed in the sonic hedgehog (SHH) subgroup and in a
small subset of Group 3 and Group 4 MB tumors. Using a cell-based three-dimensional cell motility assay combined
with live-cell imaging, we investigated whether the c-Met ligand HGF could drive dissemination of MB cells expressing
high levels of c-Met, and determined downstream effector mechanisms of this process. We detected variable c-Met
expression in different established human MB cell lines, and we found that in lines expressing high c-Met levels,
HGF promoted cell dissemination and invasiveness. Specifically, HGF-induced c-Met activation enhanced the capability
of the individual cells to migrate in a JNK-dependent manner. Additionally, we identified the Ser/Thr kinase MAP4K4 as
a novel driver of c-Met-induced invasive cell dissemination. This increased invasive motility was due to MAP4K4 control
of F-actin dynamics in structures required for migration and invasion. Thus, MAP4K4 couples growth factor signaling to
actin cytoskeleton regulation in tumor cells, suggesting that MAP4K4 could present a promising novel target to
be evaluated for treating growth factor-induced dissemination of MB tumors of different subgroups and of other
human cancers.
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Background
Medulloblastoma (MB) is the most common malignant
brain tumor in children and accounts for approximately
10% of all pediatric cancer deaths. MB is thought to arise
from neuronal progenitor cells harboring defects in the
regulation of gene expression that normally controls
growth and development of the cerebellum (Roussel and
Hatten 2011). MB cells can disseminate from the primary
tumor in the cerebellum throughout the central nervous
system and cause metastatic disease in as many as 30%
of patients at diagnosis. MB comprises a diverse set of
tumors (Northcott et al. 2012a) and four molecular
subgroups with differential metastatic potential, named
WNT (wingless), SHH (sonic hedgehog), Group 3, and
Group 4 (Taylor et al. 2012), have been classified, which
remain stable from primary to recurrent MB (Ramaswamy
et al. 2013). Treatments that specifically target metastatic
dissemination are needed to improve patient survival and
reduce treatment-related morbidity.
The receptor tyrosine kinase mesenchymal epithelial
transition factor (c-Met) is activated by hepatocyte growth
factor/scatter factor (HGF), its only known ligand to date,
which triggers phosphorylation of Tyr1230, Tyr1234, and
Tyr1235 in the intracellular domain of c-Met. c-Met phos-
phorylation promotes the induction of various intracellular
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signaling pathways (Trusolino et al. 2010) to control cell
proliferation, survival, and mobilization through the regu-
lation of integrin function and cytoskeleton dynamics
(Trusolino et al. 2010). Aberrant c-Met activation occurs
in various human cancers in different organs, including
the brain, and is associated with disease progression and
metastatic dissemination (Sierra and Tsao 2011; Li et al.
2005; Joo et al. 2012).
c-Met is expressed in surgical MB specimens and MB
cell lines and its expression and the expression of its lig-
and HGF is associated with significantly worse outcome
in patients (Li et al. 2005). Along with SHH, increased ex-
pression of HGF promotes formation and growth of MB
tumors in mice (Binning et al. 2008). An increased level
of HGF was found sufficient to drive invasiveness of
orthotopically xenografted DAOY MB cells (Li et al. 2005).
No activating mutation has been reported for MB-expressed
c-Met to date, whereas increased c-Met activity has been
linked to proliferation, anti-apoptosis, and migration in MB
(Li et al. 2005; Provencal et al. 2009; Guessous et al. 2012;
Guessous et al. 2010; Kongkham et al. 2010; Onvani et al.
2012). c-Met was found to increase the expression of the
transcription factor v-myc avian myelocytomatosis viral
oncogene homolog (MYC) (Li et al. 2008), which is the
hallmark of the most aggressive form of MB (Taylor et al.
2012). Pro-metastatic functions of c-Met are supported by
the hyaluronan (HA) receptor CD44 and in particular
by its transcript variant CD44v6, which supports c-Met-
dependent signaling (Orian-Rousseau et al. 2002). Al-
though CD44 expression has been associated with WNT
and SHH signaling in MB, it’s expression has not yet been
analyzed in MB (Katoh and Katoh 2009; Asuthkar et al.
2012).
The molecular mechanisms and downstream effectors
that mediate HGF-induced MB cell dissemination are in-
completely understood. Herein we used cell-based in vitro
two- and three-dimensional (2D/3D) motility assays com-
bined with live-cell imaging and biochemical approaches
to investigate and characterize potentially druggable medi-
ators of HGF-c-Met-induced MB cell dissemination.
Results
c-Met and its co-receptor CD44 are highly expressed in a
subset of MB tumors and patient derived cell lines
To determine the potential clinical relevance of c-Met in
larger cohorts of MB, we compared the mRNA expres-
sion levels of c-Met in the Gilbertson, the Kool and the
Delattre datasets available through the R2 platform for
visualization and analysis of the microarray data. As con-
trol, we used nine cerebellum samples of patients aged
between 23 and 50 years. We found that the median
mRNA level of c-Met and its ligand HGF in MB tumors
from these three different primary sample cohorts were
clearly below that of normal human cerebellum (Figure 1A).
However, a sub-population of MB tumors averaging 17.5%
(Figure 1A, c-Met high) showed significantly increased
c-Met expression. Moreover, the same datasets revealed
high mRNA expression of the c-Met co-receptor CD44
(Orian-Rousseau et al. 2002) in all MB tumor samples.
By analyzing 103 primary MB tumors of the Northcott
103 dataset (Northcott et al. 2011), Onvani et al. described
the association of c-Met with the SHH subgroup (Onvani
et al. 2012). We confirmed this finding using the 285
tumors of the MAGIC dataset (Northcott et al. 2012b)
(Additional file 1: Figure S1A). An analogous but less
marked association was also observed for HGF (Additional
file 1: Figure S1B), but not for CD44 (Additional file 1:
Figure S1C). Using quantitative real-time PCR (Figure 1B)
and immunoblotting (IB) approaches (Figure 1C), we de-
tected high c-Met, CD44, and CD44v6 expression both at
the mRNA and protein levels in DAOY and UW228 cell
lines, and much less (c-Met) or no (CD44/CD44v6) ex-
pression in D341 and D425 cell lines. Interestingly, three
bands were detected in the anti-CD44v6 blot (Figure 1C,
arrowheads), suggesting the presence of different CD44
isoforms with incorporated v6 variable region. DAOY cells
are sensitive to sonic hedgehog (Gotschel et al. 2013) and
considered a SHH-like MB cell line, whereas D341 is
considered a group 3 cell line (Snuderl et al. 2013). We
confirmed surface expression of c-Met, CD44, and CD44v6
on DAOY (Figure 1D) and UW228 cell lines (not shown)
by flow cytometry. This analysis revealed that >90% of
DAOY cells expressed c-Met, 100% expressed CD44, while
only approximately 40% expressed the CD44v6 isoform.
We therefore continued our studies by focusing specifically
on c-Met and by studying what effects c-Met activation by
its ligand HGF may have on cell migration and invasion
and which effector pathways are needed to mediate the
c-Met responses.
HGF stimulation activates JNK and MAPK/ERK pathways
and promotes motility
To determine dynamics of c-Met-induced ERK and JNK
activation in DAOY and UW228 cells, we stimulated the
cells with HGF in a time course experiment. We found
that HGF stimulation of DAOY or UW228 cells promotes
rapid phosphorylation of c-Met (IB p-c-Met) within five to
ten min (Figure 2A) and the concomitant activation of the
downstream effector extracellular-signal-regulated kinase
(ERK, IB p-ERK) (Figure 2B). c-Met and ERK phos-
phorylations were blocked when the cells were pretreated
for 2 h with the ATP-competitive c-Met inhibitor PHA-
665752 (Christensen et al. 2003) but not with the non
ATP-competitive inhibitor ARQ197 (Munshi et al. 2010)
(Figure 2B). However, we found that 24 h ARQ197 pre-
treatment was necessary to block acute, HGF-induced
c-Met signaling (Figure 2C). c-Met can activate the c-Jun
N-terminal kinase (JNK) (Rodrigues et al. 1997), which
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controls growth and invasion of MB cells (Zavarella et al.
2009). Consistently, we detected PHA-665752-sensitive
phosphorylation of mainly the p46 isoform of JNK within
five to ten minutes of HGF stimulation (Figure 2D). Inter-
estingly, 24 h treatment with ARQ197 (Figure 2C) also
caused increased JNK phosphorylation by an unknown
mechanism, which was not further increase by HGF stimu-
lation, because c-Met activity was blocked. To determine
whether HGF stimulation and/or c-Met inhibition affected
cell viability and/or proliferation, we performed a
Figure 1 Expression of c-Met in medulloblastoma clinical samples and cell lines. (A) Expression analysis of c-Met, HGF and CD44 in three
different MB tumor collections (ntotal = 195) and in normal adult cerebellum (n = 9). (B) Comparative quantitative real-time PCR expression analysis
of c-Met, CD44 and CD44v6 in established MB cell lines and adult cerebellum sample. (C) Expression and activation analysis of the c-Met pathway,
CD44, and CD44v6 by immunoblotting (IB) in four different MB cell lines using the antibodies indicated to the right of the blots. (D) Flow cytometry
analysis of DAOY cells quantifying surface expression of c-Met, CD44, and CD44v6. Dot plots compare expressions of c-Met and CD44 or c-Met and
CD44v6. Histograms show relative fluorescence intensities of isotype control and specific antibody samples.
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Figure 2 c-Met is activated by HGF in medulloblastoma cells and promotes wound closure. (A) IB of DAOY and UW228 lysates of cells after
HGF stimulation. Antibodies used as indicated to the right of the panels. B) IB analysis of PHA-665752 and ARQ 197 (1 μM, 2 h pretreatment) effects on
HGF-induced (50 ng/mL, 10 min) c-Met and ERK pathway activation (anti-p-c-Met and anti-pERK, respectively). (C) IB analysis as in B of the effect of
prolonged (24 h) pretreatment with ARQ197 inhibitor on HGF-induced c-Met and ERK activation in UW228 cells. (D) IB analysis of HGF-induced activation
of JNK and ERK in DAOY cells (20 ng/mL HGF −/+ 250 nM PHA-665752). (E) Schematic showing how the area covered by the cells in the Oris migration
assay was determined. Light grey: cell monolayer at T0h. White: gap after removal of the plug. Dark grey: area covered by cells at T10h. (F) Quantification
(means + S.D.) of Oris migration assays using DAOY or UW228 cells in HGF-treated (20 ng/mL) medium containing 0% FCS and pharmacological
inhibitors (PHA-665752 and ARQ 197, both at 125 nM). (G) As F) but progression of gap closure shown for 0–10 h only.
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tetrazolium salt WST assay on DAOY and UW228 cells
treated with various combinations of HGF and PHA-
665752 or ARQ197. Corresponding to c-Met expression
levels (high in DAOY and UW228, low in D425), prolifera-
tion/viability was effectively reduced by the c-Met inhibi-
tors in DAOY and UW228 cells and only moderately
affected in D425 cells (Additional file 2: Figure S2). To
monitor HGF-induced cell migration, we used the Oris
migration assay (Gough et al. 2011) (Figure 2E) and mea-
sured the effect of HGF-c-Met signaling on the cells’
capability to close a circular gap created by the inser-
tion of a rubber stopper into the well that prevented
cell attachment and growth (Figure 2F). Using time
lapsed video microcopy imaging, we found that HGF
treatment significantly accelerated gap closure within 24 h -
both under serum-free (Figure 2F) and 10% serum
(Additional file 3: Figure S3A) conditions. Importantly,
time-lapse imaging showed that HGF treatment strikingly
increased migration already within 5 h of incubation
(Figure 2G). In DAOY cells, PHA-665752 treatment in
the absence of ectopically added HGF reduced gap
closure by nearly 50%, suggesting that an endogenous
or a serum-derived factor activates the c-Met signaling
axis and promotes pro-migratory signals (Additional file 3:
Figure S3B). Overall, we showed that c-Met signaling
was active in MB cells, that it was further activated by the
exogenous addition of HGF and that it contributed to cell
migration on 2D surfaces.
HGF promotes single cell motility and invasiveness
In assays that measure the area covered by cells such as
wound healing assays or end-point Oris migration assay,
it is not possible to discriminate between individual cell
migration and proliferation. To determine whether HGF-
induced c-Met activation indeed caused increased cell mo-
tility, we determined the speed of single cells. Towards
that end, we measured the pathlength of single cells that
migrated over a given time (speed) by time-lapse video
microscopy. We found that HGF promoted a twofold
increase in cell speed both in DAOY and UW228 cells
(Figure 3A), which was blunted when c-Met was pharma-
cologically inhibited by either PHA-665752 or ARQ197.
HGF also significantly increased single cell motility in
the matrigel invasion in a c-Met-dependent manner
(Figure 3B). However, the matrigel invasion assays does
not permit monitoring the behavior of single cells inside a
3D matrix and measuring their speed of migration. To
solve that problem, we developed a versatile micro bead
invasion assay for MB cells and assessed cell dissemination
from the beads into the surrounding collagen. Import-
antly, cells migrating inside the matrix are fully accessible
for fixed- and live-cell microscopy (Figure 3C, upper). We
found that HGF or epidermal growth factor (EGF) treat-
ment promoted massive cell dissemination (Figure 3C
and D). As expected, PHA-665752 prevented HGF- but
not EGF-induced dissemination, confirming the specifi-
city of this compound for the c-Met receptor tyrosine
kinase. We observed that cells migrating in the collagen
matrix displayed marked, F-actin rich invasive protru-
sions at the leading edges (Figure 3E), suggesting that
local F-actin polymerization in the lamellipodia of cells
is instrumental for motility. Taken together, these data
demonstrate that HGF triggers dissemination of MB cells in
2D and 3D environments by accelerating motility at the sin-
gle cell level. We furthermore detected enhanced local F-
actin polymerization, suggesting F-actin turnover acting at
the leading edge in HGF-stimulated cells as driving force.
JNK and MAP4K4 are downstream effectors of HGF-induced
motility
JNK is highly expressed in the brain and controls neur-
onal cell migration during development (Zdrojewska and
Coffey 2014) and in MB cells, HGF stimulation promoted
JNK activation (Figure 2D). To test whether JNK activity
was necessary for HGF-induced motility, we treated MB
cells with the JNK inhibitor SP600125 (Han et al. 2001).
We found that HGF-stimulated single cell motility (speed)
was markedly reduced when JNK activity was blocked
(Figure 4A). Interestingly, the ablation of JNK activity
in the absence of HGF significantly reduced speed of sin-
gle UW228 but not DAOY cells, indicating that serum-
dependent motility bypasses JNK in DAOY but not in
UW228 cells (Figure 4A) and suggesting different JNK
pathway regulation in these closely related cell lines. We
confirmed the sensitivity of HGF-induced single cell
motility to JNK inhibition with the two additional JNK
inhibitors JIP-1 (153–163) and AEG 3482 (Additional
file 4: Figure S4). One upstream kinase of the JNK sig-
naling pathway is the Ser/Thr kinase mitogen-activated
protein kinase kinase kinase kinase 4 (MAP4K4) (Su et al.
1997). MAP4K4 mediates HGF effects on anchorage-
independent growth and invasiveness (Wright et al. 2003),
promotes F-actin dynamics in lamellipodia and cell motil-
ity (Baumgartner et al. 2006; Ma and Baumgartner 2014)
and contributes to the progression of solid tumors in
humans (Collins et al. 2006; Hao et al. 2010; Liang et al.
2008; Liu et al. 2011; Qiu et al. 2012). In human MB sam-
ples of all four subgroups, MAP4K4 is highly expressed,
most significantly in the SHH and Group 4 subgroups
(Additional file 1: Figure S1D). Depletion of MAP4K4
using a small interfering RNA (siRNA) approach abro-
gated the pro-migratory effect of HGF and also signifi-
cantly reduced steady-state motility (Figure 4B). Thus,
HGF-Met signaling increases speed of single migrating
cells through mechanisms requiring JNK activity and
MAP4K4 function, suggesting that these two kinases
are essential regulators of MB cell dissemination.
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Figure 3 (See legend on next page.)
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HGF promotes cortical actin polymerization and
membrane protrusion
Increased F-actin dynamics and cell motility indicated
that c-Met could be active in lamellipodia to control
F-actin dynamics in these structures. We used immuno-
fluorescence (IF) microscopy to localize c-Met and p-
c-Met in MB cells. Indeed, in lamellipodia of DAOY
(Figure 5A, arrowheads) and UW228 (Additional file 5:
Figure S5A) cells, we detected accumulations of c-Met
and p-c-Met (Figure 5A, arrows). To test whether c-Met
activation promoted cortical actin dynamics (Rottner and
Stradal 2011), we stimulated MB cells with HGF and mon-
itored immediate and late changes in cortical F-actin by
immunofluorescence analysis (Figure 5B) and live cell im-
aging (movies Additional file 6: SM1, Additional file 7:
SM2, Additional file 8:SM3), respectively. Interestingly,
within 15 min we observed de novo synthesis of lamelli-
podial branched F-actin in the extension zone in HGF-
stimulated cells (Figure 5B, magnifications), which was
prevented when cells were pretreated with PHA-665752.
We also observed accelerated and more prominent
cortical F-actin turnover in HGF-stimulated UW228
cells (movies Additional file 6: SM1, Additional file 7:
SM2, Additional file 8: SM3). To test whether MAP4K4
could promote cortical F-actin dynamics in MB cells,
we expressed either enhanced green fluorescent pro-
tein (EGFP)-tagged wild-type (EGFP-MAP4K4-wt) or a
kinase-defective (EGFP-MAP4K4-k/d) mutant of MAP4K4
in DAOY cells together with Lifeact fused to mCherry
(LA-mCherry). We monitored F-actin dynamics by con-
focal live cell microscopy and quantified morphodynamic
alterations of cell protrusions by kymography (Figure 5C
and Additional file 5: Figure S5B). We found that F-actin
polymerization dynamics in lamellipodia were significantly
higher in cells expressing MAP4K4-wt and blunted in cells
expressing MAP4K4-k/d. Interestingly, cells depleted of
MAP4K4 by inducible short hairpin RNA expression
(shRNA, see below) were also no longer able to respond
to HGF stimulation with scattering (Figure 5D) and
morphological alterations (contraction, measured as area
covered per cell, 5E). Specifically, we observed that
HGF-induced cell scattering evident in a culture of semi-
confluent cells 24 h after HGF stimulation and resulting in
dissociated cells with few cell-cell contacts, was abrogated
by MAP4K4 depletion using shRNA. Reduced scattering
may in part be due to reduced motility of single cells
(Figure 5F). However, in shRNA MAP4K4-expressing cells,
we also observed more cells with intact cell-cell contacts,
suggesting that MAP4K4 effects on cell dissemination
impact different levels of cell migration control. Taken
together, our data show that MAP4K4 orchestrates HGF-
induced morphodynamic processes and MB cell motility
by controlling F-actin cytoskeleton dynamics and its
depletion reduces the capability of MB cells to scatter
in response to HGF.
MAP4K4 promotes HGF-induced single cell scattering and
collagen invasion
To test whether MAP4K4 was driving HGF-induced in-
vasive motility in collagen, we used MB cells expressing
doxycycline (doxy)-inducible scrambled control shRNAs
(shScr) or shRNAs targeting MAP4K4 (shMAP4K4)
(Additional file 5: Figure S5C) in the micro bead inva-
sion assay. Confocal microscopy imaging showed that
HGF-promoted dissemination was markedly reduced
in MAP4K4-depleted cells (Figure 6A). To quantify in-
vasiveness of larger numbers of cells, we visualized cell
nuclei (Figure 6B) and measured the distance between
the bead and the individual nuclei (Figure 6C). We found
that HGF-induced single cell dissemination in 3D was sig-
nificantly reduced when MAP4K4 was depleted, both in
0% and 10% FCS medium. Importantly, HGF-stimulated
shScr cells displayed considerably higher F-actin content
at the leading edge than did MAP4K4-depleted cells
(Figure 6D), indicating that MAP4K4-induced F-actin
polymerization activity (Figure 5C–E) was also needed
for forming invasive protrusions during cell migration
in collagen. In conclusion, HGF promoted MB cell dis-
semination in collagen is driven by MAP4K4, probably
by triggering the invasive, F-actin-rich membrane protru-
sions required for cells to invade and migrate (Figure 6E).
Discussion
In this study, we have investigated the functional signifi-
cance of the HGF-c-Met signaling pathway for MB cell
dissemination. We found that c-Met expression is upreg-
ulated in the SHH subgroup and in a subset of Group 3
and Group 4 MB tumors, as well as in some established
(See figure on previous page.)
Figure 3 HGF promotes invasive motility of single medulloblastoma cells. (A) Single cell motility of DAOY and UW228 cells was measured using
live cell imaging (HGF: 20 ng/mL, ARQ197 and PHA-665752 250 nM). Box plots of three independent experiments are shown. (B) Boyden chamber
invasion assay under conditions as described in (A). Mean total numbers of cells transmigrated and S.D. of representative triplicate experiment
are shown. Statistical analysis: T-test, * = 0.0454, ** = 0.0038. (C) Upper: schematic of microbead invasion assay setup. Lower: microbeads coated with
DAOY cells were embedded in collagen and cells were allowed to disseminate for 24 h. Confocal microscopy analysis of LA-EGFP fluorescence 24 h
after embedding is shown (left: maximum intensity projection of Z-stacks, right: single cross-section through middle of beads). D) Quantification of
mean and range of cell dissemination from microbeads shown in C (triplicate measurements, ten beads quantified per measurement, dot plot with
SD). E) High-resolution confocal images of an HGF-induced (20 ng/mL) LA-EGFP expressing DAOY cell migrating in collagen. F-actin distribution is
shown as inverted grey scale. Arrow: direction of migration. Note high F-actin content in invasive protrusions at leading edge of the cell.
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SHH MB laboratory cell lines. We demonstrated that c-
Met activation by its ligand HGF promotes single cell mo-
tility of MB cells and their invasion into Matrigel and 3D
collagen gels. We further showed that HGF-induced mo-
tile and invasive cell behavior requires the Ser/Thr kinase
MAP4K4, which controls F-actin cytoskeleton dynamics in
cellular protrusions necessary for motility and invasiveness.
Thus, our studies reveal a novel, growth factor-dependent
signaling circuit that promotes MB cell dissemination
through MAP4K4-dependent cytoskeleton regulation, and
underscore the necessity of patient stratification based on
growth factor sensitivity of the tumor for rational targeting
of cancer promoting signaling pathways.
Others and we have revealed a striking association of
c-Met expression with SHH MB ((Onvani et al. 2012) and
Additional file 1: Figure S1A) and we found that c-Met
is overexpressed in approximately 18% of MB tumors
compared to cerebellum controls. It is possible that c-Met
could contribute to tumor progression by causing dissem-
ination of the subset of recurrent SHH tumors reported
recently (Ramaswamy et al. 2013). Importantly, c-Met
function could also contribute to MB tumor cell dissemin-
ation in other subgroups by driving cell motility. However,
other cellular parameters such as the capability to survive
in the CSF or to colonize the new niche will be as import-
ant as well, and which could explain the discrepancy in
the relative clinical outcomes between c-Met-high SHH
and for example c-Met-low Group 3 tumors. Future
studies examining large cohorts of patients in a subgroup-
specific manner will now be required to fully appreciate
the role of c-Met signaling in this context. Although the
expression of the c-Met co-receptor CD44 was high in all
MB tumor samples analyzed, its role in MB is unclear and
further studies will also be needed here to reveal c-Met-
related and un-related effects of CD44 in MB pathogen-
esis. Unlike CD44 expression in tumor samples, CD44
expression in MB cell lines was restricted to those ex-
pressing c-Met. Of these, only 40% co-expressed also
the HGF-c-Met-interacting variant isoform CD44v6. In
glioblastoma, CD44 expression conferred growth ad-
vantages and therapeutic resistance (Xu et al. 2010) and
it remains to be resolved whether analogous mecha-
nisms are also active in MB, in particular in the context
of c-Met interaction with CD44v6.
Several earlier studies have implicated a role of HGF-
c-Met in MB growth and dissemination and scratch
wound healing assays revealed the involvement of c-Met
in wound closure (Kongkham et al. 2010). However, it
remained unclear whether c-Met inhibition reduced MB
cell dissemination because it impaired proliferation or
because it impaired cell motility. We clarified this point
by providing direct evidence that HGF-c-Met function
promotes the capability of MB cells to migrate, which
ultimately accelerates their dissemination both in 2D and
3D environments. It can be assumed that the dual func-
tion of c-Met, stimulation of proliferation and of single
cell motility is effective in other cell types or tumor cells
expressing high c-Met and explains in part the effective
tumorigenic activity of this receptor.
How c-Met-induced JNK promotes MB cell motility is
not known; it is possible that JNK is relevant in MB cells
for proper function of the microtubule skeleton during
Figure 4 HGF-induced single cell motility is mediated by the
Ser/Thr kinases JNK and MAP4K4. (A) Motility of single cells
migrating on flat 2D surfaces in the absence or presence of HGF
(20 ng/mL) and the JNK inhibitor SP665757 (10 ng/mL). Box plots of
three independent experiments are shown. (B) Same experimental
approach as in (A) but instead of using a pharmacological inhibitor,
MAP4K4 was depleted from cells using validated MAP4K4-specific
(+) siRNA. (−) is a negative control siRNA .
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Figure 5 (See legend on next page.)
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Figure 6 MAP4K4 drives HGF-induced cell dissemination in fibrillar collagen. (A) Z-stack maximum intensity projection of collagen embedded,
disseminating DAOY-doxy-MAP4K4 cells. Short hairpin RNA expression was induced by doxy stimulation for 48 h before the start of the experiment
(lower panel). Cells were stimulated with HGF (20 ng/mL) for 24 h. Green: F-actin, blue: DNA. (B) Representative montaged images of inverted
grey-scale fluorescence of nuclear DNA to visualize cell dissemination. shRNA control or shMAP4K4_1/_3 expression with doxycycline and FCS
and HGF treatments as indicated. C) Quantification of average velocities of disseminating cells with treatments as indicated. The averages of
three independent experiments and S.D. are shown. D) High resolution confocal Z-stack of invading shScr and shMAP4K4 LA-EGFP cells. Note
reduced F-actin in invasive protrusions of shMAP4K4 cells E) Schematic representation of signaling pathways investigated. Highlight blue is
the central MAP4K4 controlled machinery that we propose to drive the dynamic remodeling of the actin cytoskeleton required for cell dissemination
downstream of growth factor signaling.
(See figure on previous page.)
Figure 5 HGF promotes cortical actin dynamics in medulloblastoma cells. (A) Immunofluorescence analysis (IFA) of c-Met and phosphorylated
c-Met (p-c-Met) localization in lamellipodia of DAOY cells. Color overlay and inverted grey-scale images of p-c-Met (red), actin (green) and c-Met (blue)
are shown. Magnifications are 4× of boxed area in overlay. Arrows indicate c-Met-rich lamellipodia. (B) IFA of Alexa-488-phalloidin-stained F-actin
cytoskeletons in un-stimulated and HGF-stimulated (20 ng/mL, t = 10 min) DAOY cells, −/+ PHA-665752 (500 nM). Inverted grey-scale images
of Alexa-488-phalloidin fluorescence are shown. Magnifications are 4× of boxed areas. Lower left magnification is 4× of sheet-like protrusion
in b). Arrows: filopodia, arrowheads: leading edge of F-actin sheet (extension zone, see schematic). (C) F-actin dynamics in DAOY cells transfected with
LA-mCherry and either enhanced green fluorescent protein-tagged, wild-type (wt) or kinase-defective (k/d) MAP4K4 were recorded by confocal live cell
microscopy imaging. See Additional file 5: Figure S5 for still images of representative cells. Dot blots show protrusion lengths in control cells or cells
expressing either EGFP-MAP4K4-wt or EGFP-MAP4K4-k/d. (D) Still images of time-lapse movies of DAOY-LA-EGFP-shScr or DAOY-LA-EGFP-shMAP4K4_1
cells stimulated with HGF (20 ng/mL). T0 is 0 h and T18 is 18 h after HGF stimulation. Inverted grey-scale of LA-EGFP fluorescence (F-actin cytoskeleton)
is shown. (E) Cells were treated as described in (D). Box plots of areas in pixels covered by individual cells quantified at T0 and T18. (F) Box plot of
speeds of single sh control or shMAP4K4 cells in the presence of HGF. Statistical analysis: T-test (*: P = 0.0208).
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motile processes through its activity toward the micro-
tubule regulatory proteins superior cervical ganglion 10
(SCG10), doublecortin (DCX) (Zdrojewska and Coffey
2014) or microtubule-associated protein 1b (MAP1b)
(Yamasaki et al. 2011). In addition to JNK, we identified
MAP4K4 as a novel kinase essential for efficient dis-
semination of MB cells. MAP4K4 and its murine (Nck-
interacting kinase), fly (misshapen) and worm (MIG15)
orthologs are evolutionary conserved and control migra-
tion of both neurons (Chapman et al. 2008; Poinat et al.
2002; Shakir et al. 2006; Teuliere et al. 2011) and cancer
cells (Collins et al. 2006; Wright et al. 2003; Hao et al.
2010; Liang et al. 2008; Liu et al. 2011; Qiu et al. 2012).
Although its function downstream of HGF has been
suggested (Wright et al. 2003), our findings are the first
to demonstrate the involvement of MAP4K4 downstream
of c-Met in tumor cells. Depletion of MAP4K4 reduced
dissemination and the accumulation of F-actin in focal
invasion structures. This finding is consistent with estab-
lished functions of MAP4K4 as a regulator of cortical actin
dynamics (Baumgartner et al. 2006; Poinat et al. 2002;
Teuliere et al. 2011; Ma and Baumgartner 2014; Wright
et al. 2003; Yan et al. 2001) and it is thus conceivable that
MAP4K4 triggers and coordinates spatio-temporal actin
polymerization and turnover, both of which are essential
for efficient cell movement. Thus, MAP4K4 function is
likely needed at the single cell level to trigger invasive
cell protrusions, which in turn are necessary for motility
and invasiveness of MB tumors. Although MAP4K4 is an
established upstream activator of JNK (Machida et al.
2004), we could not provide convincing evidence that
MAP4K4 is active in this function in MB cells as well
(not shown). Hence, we concluded that while both kinases
are essential for MB motility, they do probably act in par-
allel pathways rather than in a serial one. Considering that
MAP4K4 is activated by various growth factors including
HGF, PDGF (Yan et al. 2001), TNFα (Yao et al. 1999)
or integrin activation (Poinat et al. 2002), we assume
that several different receptor-mediated pathways trig-
ger MAP4K4-dependent MB cell dissemination. Conse-
quently, MAP4K4 could act as a hub to divert extracellular
derived cues toward morphodynamic processes promoting
motility and invasiveness (Figure 6E). Thus, we now need
to further refine our understanding of upstream activators
and downstream effectors of MAP4K4 in MB, because of
its potential significance as a druggable anti-metastatic
target for a recently synthetized novel MAP4K4 inhibi-
tor (Crawford et al. 2014).
In summary, we have shown that the HGF-c-Met sig-
naling pathway promotes MB cell dissemination by enab-
ling cell dissociation, rapid movement and efficient matrix
invasion of single cells. We revealed the implication of
the Ser/Thr kinase MAP4K4 and its cytoskeleton mod-
ulatory functions and suggest it as a potential novel
anti-metastatic target worth to investigate further. Fi-
nally, the pro-migratory functions of MAP4K4 through
cytoskeleton regulation revealed herein might contribute
to the metastatic progression of SHH subgroup and other
MB tumors where MAP4K4 is overexpressed.
Conclusions
We have established a novel, cell-based assay to monitor
cancer cell dissemination in three-dimensional matrices.
We show for the first time that HGF-induced c-Met ac-
tivation enhanced the speed of migration of the individual
Medulloblastoma cells and show that the Ser/Thr kinase
MAP4K4 is an essential mediator in this process. We
conclude that MAP4K4 couples growth factor signaling
to actin cytoskeleton regulation in tumor cells, suggest-
ing that MAP4K4 could be a promising novel target to
be evaluated for treating growth factor-induced dissemin-
ation of Medulloblastoma tumors of different subgroups
and of other human cancers.
Methods
Ethics statement
This work was conducted according to the ethical guide-
lines of the University of Zürich. No donor material was
used.
Expression analysis using R2 database
All data used are accessible through the open access plat-
form R2 for visualization and analysis of the microarray data
(http://r2.amc.nl). The following datasets were used: Delattre
54 MAS 5.0 – u133p2 (54 MB samples), Gilbertson 76
MAS 5.0 – u133p2 (76 pediatric MB samples, PubMed link:
22722829), Kool 62 MAS 5.0 – u133p2 (62 human MB
samples, PubMed link 18769486), Northcott 103 rma_
sketch – huex10t (103 primary MB samples, PubMed link
20823417) and MAGIC 285 rma-sketch – hugene11t (285
primary MB samples, PubMed link 22832581) Analysis was
performed as described in (Fiaschetti et al. 2014). The nine
normal cerebellum samples are from human subject aged as
follows: Donor 1–25 year old male; donor 2–38 year old
male; donor 3–39 year old female; donor 4–30 year old
male; donor 5–35 year old male; donor 6–52 year old male;
donor 7–50 year old female; donor 8–48 year old female;
donor 9–53 year old female; donor 10–23 year old female.
Reagents
HGF: 0.25 μM= 20 ng/mL (Preprotech), JIP-1 (153–163)
(1565, Tocris), ARQ 197 (A-1109, Active Biochemicals),
PHA-665752 10 μM, AEG 3482 5 μM (Axon), (Selleck
Chemicals, 10 μM). SP600125 20 μM (S5567), Doxycycline
(44577) Blasticidin (15205) (Sigma-Aldrich), AEG 3482
(1291, Axon Medchem).
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Cell culture
DAOY, UW228-2, D341, and D425 cells were grown as
described in (Fiaschetti et al. 2014). DAOY-LA-EGFP were
generated by lentiviral transduction of DAOY with cells
pLenti-LA-EGFP.
Transfection
5 × 105 cells/well were seeded in 6-well plates and 24 h
later transiently transfected using Jet-Pei (101–10 Polyplus),
with 2.5 μg of plasmids expressing LA-mCherry (pLenti-
LA-mCherry) and either MAP4K4-wt (pEGFP-C2
NIKwt) or MAP4K4-kinase dead (pEGFP-C2 NIKD152N)
(Baumgartner et al. 2006).
Immunoblotting
RIPA buffer lysates were probed with the following primary
and secondary antibodies: phospho-c-Met (44888, Life
Technologies), c-Met (3148), phospho-STAT3 (9131),
STAT3 (9132), phospho-JNK (4668), JNK (9258), phospho-
ERK1/2 (9101), ERK1/2 (9102), CD44 (3578) (Cell Signaling),
anti-MAP4K4 (80418, Abcam), α-tubulin (T9026, Sigma-
Aldrich), and CD44v6 (MAB4073, clone VFF-18, Millipore),
anti-mouse horseradish peroxidase (HRP)-linked (7076)
and anti-rabbit HRP-linked (7074) (Cell Signaling).
Primary antibodies were diluted 1:1000 except for
α-tubulin (1:40000). Secondary antibodies were diluted
1:2000.
Immunofluorescence analysis
Cells were fixed and treated as described in (Ma and
Baumgartner 2014). Primary antibodies were diluted 1:200
and incubated overnight at 4°C: α-phospho-c-Met (#44888,
Life Technologies), c-Met (3148), CD44 (3578) (Cell
Signaling), α-tubulin (T9026, Sigma-Aldrich), Alexa488-
(A12379, Life Technologies), Cy3- (711-165-152), and Cy5-
coupled (415-175-166) secondary antibodies were used
(Jackson Immuno Research). Secondary antibodies and
tetramethylrhodamine isothiocyanate-coupled phalloidin
(Sigma-Aldrich) were diluted 1:500. Images were acquired
on an Axioskop 2 mot plus fluorescence microscope
(Zeiss).
Confocal live cell imaging
DAOY and UW228 cells stably expressing LA-EGFP were
seeded in serum-free HEPES-buffered (25 mM) medium
overnight on ibidi 8-well slides (5000 cells/well). PHA-
665752 (500 nM) was added 1 h prior to and HGF (20 ng/
mL) was added at the start of image acquisition in SP8
Leica confocal microscope. A 63× water immersion ob-
jective was used to acquire 60 Z-stacks of six images of
EGFP fluorescence/timepoint (15 s intervals, 15 min).
Average intensity projections of the stacks were assembled
into QuickTime movies (10 fps, 150x speed).
Oris migration assay
The Oris™ 96-well cell migration assay kit (CMA1.101,
Platypus Technologies) was used (3.5 × 104 cells seeded/
well). After plug removal, cells were treated without or
with HGF (20 ng/ml) and PHA-665752 or ARQ197. Cell
migration was monitored for 25 h using an automated
ImageXpress Micro 2 (Molecular Devices) equipped with
environmental control. Images were acquired at 5 h inter-
vals with a 10× 0.2 NA Plan Apo objective (Nikon) and
Roper CoolSNAP HQ camera (Roper Scientific). Wound
closure was quantified using the threshold method in the
MetaXpress software (Version MX 3.1.0.93).
Matrigel invasion assay
A total of 25’000 cells were suspended in complete medium
and seeded on the upper side of the Matrigel-coated mem-
brane (BD 354480). Complete medium with or without
20 ng/ml HGF as used in the lower chamber. After 24 h,
transmigrated cells were fixed with 4% PFA and stained
with 0.05% crystal violet.
Single cell motility assay
Cells were seeded on 96-well glass bottom plates (In Vitro
Scientific)) at 40% confluency in assay medium with or
without HGF (20 ng/mL) and cell motility was acquired
using the ImageXpress Micro 2 microscope. Cell speed
(total path length/time) was determined by manually
tracking the cells at 5 min intervals for 6–18 h using
ImageJ software (National Institutes of Health, USA).
Flow cytometry
Cells were detached with Accutase (A6964, Sigma-Aldrich),
fixed in 0.5% PFA for 10 min and washed in 0.5% Tween
20 (P9416, Sigma-Aldrich) and collected in flow cytometry
(FC) buffer (5% FBS, 0.5% BSA, 0.1% Na-azide in PBS).
0.25 × 106 cells per sample were stained with the following
primary antibodies: CD44-Alexa488 (103016, 1:50), Isotype
control-Alexa488 (400625, 1:50) (BioLegend), c-Met-biotin
(13–8858, 1:100), c-Met (5631, 1:100) (Cell Signaling),
Isotype control-biotin (13–4301, 1:100) and CD44v6
(BMS125, 1:100) (eBioscience), and Isotype control mouse
IgG1 (02–6502, Life Technologies, 1:10 – 1:50). Sec-
ondary antibodies: anti-mouse-Alexa647 (A31571, Life
Technologies, 1:10000) and Streptavidin-PE (12–4317,
eBioscience, 1:10000). Sequential incubations (double
staining) were interrupted by three washes. Sample ac-
quisition (10000 events) in BDFACSCanto II flow cyt-
ometer (BD Bioscience).
RNA expression analysis by qRT-PCR
Total RNA was extracted using the RNeasy Mini Kit
(Qiagen, Basel, Switzerland) following the manufacturer’s
instructions 1 μg of total RNA was used as template for
reverse transcription, which was triggered by random
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hexamer primers and performed by using the High-
Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). qRT-PCR was performed under conditions
optimized for the ABI7900HT instrument, using Gene Ex-
pression Master Mix (Applied Biosystems). Probe-primer
specific for the following genes (purchased from Applied
Biosystems) were used: c-Met (Hs HS01565584_m1),
HGF (Hs00300159_m1), CD44 (HS01075854_m1), CD44v6
(Hs01075854_m1). The relative gene expression was calcu-
lated for each gene of interest by using the ΔΔCT method,
where cycle threshold (CT) values were normalized to
the housekeeping gene 18S (Hs03003631_g1) (Applied
Biosystems).
Microbead invasion assay
Approximately 500 Cytodex Microcarrier beads (Sigma
Aldrich C3275) per 1.25 × 104 LA-EGFP-DAOY cells/ml
were mixed in FACS tubes (BD Falcon T7597-5 J) and
incubated at 37°C for 6 h, followed by incubation under
rotation for 18 h. Non-adherent cells were removed. Cell-
coated microbeads were resuspended in 2.5% bovine colla-
gen I (5005-B, Advanced BioMatrix) in 96-well plate, after
polymerization of collagen overlaid with fresh medium
and treated with appropriate concentrations of c-Met in-
hibitors or HGF. After 24 h, cells were fixed with 4% PFA
and stained with Hoechst. Images were acquired using
the ImageXpress microscope. The distance between the
microbead and the nuclei of the invaded cells was mea-
sured using ImageJ software. Velocity was calculated as
the distance of displacement/time.
Generation of inducible cell lines
Inducible shRNA DAOY cell lines were generated by
lentiviral transduction. Virus was produced in HEK293T
using 4.5 μg of inducible pLV-H1TetO-RFP-Bsd vectors
encoding either MAP4K4 shRNA (Biosettia, sh_NM_
001242559 1–4) or scramble shRNA (Biosettia) along
with lentivirus packaging plasmids pRev (1 μg), pMDL
(3 μg), and pVSV (1.5 μg). Lentivirus-containing su-
pernatants were added to recipient cells in the pres-
ence of 10 μg/ml of Polybrene (AL-118, Sigma,-Aldrich).
At 48 h post-transduction, the culture medium was
removed and stable cells were selected with 5 μg/ml blas-
ticidin (15205, Sigma-Aldrich). Doxycycline-containing
(Sigma, 44577) medium was added for 48 h for shRNA
induction and protein downregulation was verified by
IB and qRT-PCR.
RNA interference
The cells were transfected using either Silencer Select
siRNA specific for MAP4K4 (ID: 18096) or Silencer
select negative control #1 (ID: 4390843) (Ambion).
Each siRNA was used at the final concentration of 5
nM in combination with Dharmafect 4 transfection
reagent (Dharmacon), according to the manufacturer’s
instructions. MAP4K4 (ID: 18096) or Silencer select nega-
tive control #1 (ID: 4390843) (Ambion) were used. After
24, 48, and 72 h cells were harvested for both mRNA and
protein extraction, to assess gene expression by qRT-PCR
and protein content by immunoblotting.
Statistical analysis
Data are represented as the mean ± SD. Statistical ana-
lyses were performed using one-way analysis of variance
(ANOVA) followed by Bonferroni’s Multiple Comparisons
test (for details please see Additional file 9: Table ST1) if
not otherwise stated. P-values <0.05 were considered
significant. [* < 0.05, ** < 0.01, *** < 0.001].
Additional files
Additional file 1: Figure S1. c-Met and HGF is specifically increased in
the SHH subgroup of medulloblastoma. Comparison of subgroup-specific
expression of (A) c-Met, (B) HGF, (C) CD44, and (D) mitogen-activated
protein kinase kinase kinase kinase 4 (MAP4K4) in the MAGIC (n = 285)
and Northcott (n = 103) datasets. Box plots show median, mean (+), and
whiskers: 5–95 percentile.
Additional file 2: Figure S2. PHA-665752 and ARQ197 block proliferation/
viability of medulloblastoma cells at low molar concentrations. DAOY
and UW228 cells in medium containing 0% or 10% FCS were treated
with PHA-665752 or ARQ197 as indicated. Proliferation and viability of
the cells were measured using the WST assay at 0 h and after 24, 48,
and 72 h.
Additional file 3: Figure S3. c-Met inhibitors block basal and HGF-induced
gap closure in medium containing 10% fetal calf serum (FCS). (A) Oris
migration assays using DAOY or UW228 cells in 10% FCS-containing
medium treated with HGF (20 ng/mL) and c-Met inhibitors PHA-665752
and ARQ 197 (125 nM). Progression of gap closure over time expressed
as area in pixels covered by cells is shown. (B) As A) but progression of
gap closure shown for 0–10 h only.
Additional file 4: Figure S4. Pharmacological JNK inhibition blocks
HGF-induced motility. Speed of single cells in the absence or presence
of HGF (20 ng/mL) and the JNK inhibitors AEG 3482 (5 μM) and JIP-1
(10 μM) was acquired using live cell microscopy imaging. Path lengths
of individual cells after 18 h are shown (bars = means).
Additional file 5: Figure S5. (A) IFA of c-Met and p-c-Met localization
in lamellipodia of UW228 cells. Color overlay and inverted grey-scale images
of p-c-Met (red), F-actin (green), and c-Met (blue) are shown. Magnifications
are 4× of boxed area. Arrows indicate c-Met-rich lamellipodia. (B) Still
images of representative cells from movies. Panels to the right of
each image show kymographic analysis of protrusion along lines
perpendicular to the cortical F-actin. C) Immunoblotting analysis of
stable, doxycycline-inducible DAOY shControl (scrambled) and shMAP4K4_3
and shMAP4K4_3 cell lines after 48 h doxycycline treatment using
concentrations as indicated.
Additional file 6: SM1F-actin dynamics in UW228 cells expressing
Lifeact (LA)-enhanced green fluorescent protein (EGFP. 15 min
recording time, 10 frames per second (fps), acceleration 150x.).
Additional file 7: SM2F-actin dynamics in HGF-stimulated (20 ng/ml,
3 h) UW228 cells expressing LA-EGFP. 15 min recording time, 10 frames
per second (fps), acceleration 150x.
Additional file 8: SM3F-actin dynamics in HGF-stimulated
(20 ng/ml, 3 h) UW228 cells expressing LA-EGFP treated with
PHA (250 nM). 15 min recording time, 10 frames per second (fps),
acceleration 150x.
Additional file 9: ST1List of statistical analyses performed.
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